Literature DB >> 8473346

Molecular cloning of human prostaglandin endoperoxide synthase type II and demonstration of expression in response to cytokines.

D A Jones1, D P Carlton, T M McIntyre, G A Zimmerman, S M Prescott.   

Abstract

Prostaglandin endoperoxide synthase (PHS) catalyzes the committed step in the biosynthesis of prostaglandins and thromboxane. We recently observed dissociation of PHS activity and enzyme mass measured in an immunoassay of endothelial cells exposed to tumor necrosis factor. These data and observations by others suggested that endothelial cells express an alternate PHS. We now report the molecular cloning of human PHS type II from an endothelial cell cDNA library. The protein encoded by this cDNA shares 61% identity with the human PHS I. Southern analysis demonstrated a single copy of PHS II and we found a polymorphism in approximately 5% of the population. PHS II mapped to chromosome 1, in contrast to PHS I, which is on chromosome 9. The PHS II cDNA hybridized strongly to a 4.3-kilobase (kb) message from endothelial cells. Stimulation of the cells with tumor necrosis factor, phorbol 12-myristate 13-acetate, lipopolysaccharide, or interleukin-1 increased mRNA levels for PHS II, and this change correlated well with increased prostacyclin biosynthesis. Cycloheximide induced PHS II mRNA without a corresponding activity increase demonstrating that translation of the 4.3-kb message is required for increased prostacyclin biosynthesis. We conclude that expression of PHS II may have important pathophysiological effects in the vasculature.

Entities:  

Mesh:

Substances:

Year:  1993        PMID: 8473346

Source DB:  PubMed          Journal:  J Biol Chem        ISSN: 0021-9258            Impact factor:   5.157


  121 in total

1.  Is cyclooxygenase-2 the alpha and the omega in cancer?

Authors:  S M Prescott
Journal:  J Clin Invest       Date:  2000-06       Impact factor: 14.808

Review 2.  Unorthodox routes to prostanoid formation: new twists in cyclooxygenase-initiated pathways.

Authors:  C N Serhan; E Oliw
Journal:  J Clin Invest       Date:  2001-06       Impact factor: 14.808

Review 3.  Risks and benefits of nonsteroidal anti-inflammatory drugs in children: a comparison with paracetamol.

Authors:  C Litalien; E Jacqz-Aigrain
Journal:  Paediatr Drugs       Date:  2001       Impact factor: 3.022

4.  Synergistic induction of cyclooxygenase-2 by transforming growth factor-beta1 and epidermal growth factor inhibits apoptosis in epithelial cells.

Authors:  D Saha; P K Datta; H Sheng; J D Morrow; M Wada; H L Moses; R D Beauchamp
Journal:  Neoplasia       Date:  1999-12       Impact factor: 5.715

5.  Increased expression of VEGF, COX-2, and Ki-67 in Barrett's esophagus: does the length matter?

Authors:  Evanthia Zampeli; George Karamanolis; George Morfopoulos; Elias Xirouchakis; Vasiliki Kalampoki; Spyros Michopoulos; Sotiria Savva; Vasilios Tzias; Irene Zouboulis-Vafiadis; Dimitrios Kamberoglou; Spiros D Ladas
Journal:  Dig Dis Sci       Date:  2011-12-07       Impact factor: 3.199

Review 6.  The COXes of Danio: from mechanistic model to experimental therapeutics.

Authors:  Stephen M Prescott; H Joseph Yost
Journal:  Proc Natl Acad Sci U S A       Date:  2002-07-01       Impact factor: 11.205

7.  Proliferation-dependent changes in release of arachidonic acid from endothelial cells.

Authors:  R E Whatley; K Satoh; G A Zimmerman; T M McIntyre; S M Prescott
Journal:  J Clin Invest       Date:  1994-11       Impact factor: 14.808

Review 8.  Cyclooxygenase-2 modulates cellular growth and promotes tumorigenesis.

Authors:  O C Trifan; T Hla
Journal:  J Cell Mol Med       Date:  2003 Jul-Sep       Impact factor: 5.310

Review 9.  [New non-steroidal anti-rheumatic drugs: selective inhibitors of inducible cyclooxygenase].

Authors:  D O Stichtenoth; H Zeidler; J C Frölich
Journal:  Med Klin (Munich)       Date:  1998-07-15

10.  Identification of specific genes and pathways involved in NSAIDs-induced apoptosis of human colon cancer cells.

Authors:  Richard-H Huang; Jianyuan Chai; Andrzej-S Tarnawski
Journal:  World J Gastroenterol       Date:  2006-10-28       Impact factor: 5.742

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.